GlaxoSmithKline plc Tops The Pharmaceuticals sector

GlaxoSmithKline plc (LON: GSK) just edges out AstraZenenca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When it comes to picking the best FTSE 100 pharmaceuticals company, for me it’s a straight knockout fight between GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and AstraZeneca (LSE: AZN) (NYSE: AZN.US).

I mean no disrespect to Shire, but its market capitalisation of a relatively low £17.1bn compared to £48.8bn for AstraZeneca and £75.5bn for GlaxoSmithKline means it really doesn’t have the clout to be a top-of-the-sector candidate.

But between the two big players, it really is a tough decision.

Is Glaxo really the best?

GlaxoSmithKlineI’ve had Glaxo in the Fool’s Beginners’ Portfolio for some time, and I made my choice based on the firm’s better response to the so-called patent cliff that was looming — the expiry of patents on some major drugs coupled with competition from generic alternatives has been threatening profits for some time.

At the time, Glaxo’s drugs pipeline was looking stronger to me. But more importantly, the company was clearly recognising the potential of newer developments in biotechnology — things like gene therapy, for example, might seriously impact on the traditional blockbuster drugs model.

And on that score, Glaxo was using its financial muscle to make some interesting acquisitions.

New broom

astrazenecaBut since then, from the opposition camp we’ve seen the driving force that is Pascal Soriot. Taking the helm of AstraZenenca in October 2012, Mr Soriot quickly set out a roadmap back to growing profits — and it’s a different approach to Glaxo’s. The new focus is back on core strengths, putting the research cash into beefing up the company’s pipeline of drug candidates, and getting rid of peripheral business that were too far from that core.

And it’s working — AstraZenenca’s earnings falls are slowing, and we’re set for a return to growth a fair bit sooner than City analysts were expecting. And it looks like dividends are set to be maintained too, where some were fearing there might need to be cuts.

But despite my respect for Mr Soriot (and I rate him as one of the FTSE 100’s top CEOs), GlaxoSmithKline still edges it for me.

Broader horizon

On short-term valuation measures, Glaxo looks better — there’s a slightly lower forward P/E (14 vs 15), a slightly higher dividend yield (5.2% vs 4.3%), and Glaxo has earnings growth forecast for 2015.

But more importantly, I prefer Glaxo’s wider view of the longer-term future, and over the coming decades I can see its openness to, and keenness to acquire, new technologies paying off.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »